What Clinical Evidence Has Been Published for Neuronox?

The current BotoxWiki evidence set includes four published randomized comparative clinical studies evaluating Neuronox, or Meditoxin where the publication explicitly identifies that name with Neuronox, across one aesthetic and three therapeutic clinical settings. [1–4]

The studies evaluated:

• moderate-to-severe glabellar lines;

• essential blepharospasm;

• spastic equinus gait in children with cerebral palsy; and

• post-stroke upper-limb spasticity.

Importantly, these are not four studies asking the same question.

The populations, treated muscles, doses, clinical objectives, endpoints and follow-up schedules differ substantially.

For this reason, the studies should be interpreted as four pieces of product-specific clinical evidence, rather than pooled into a single “Neuronox efficacy rate.”

Why Use an Evidence Map?

An evidence map keeps each result connected to the question the study actually investigated.

For each Neuronox trial, the clinically relevant sequence is:

Indication → Population → Study design → Comparator → Treatment protocol → Primary endpoint → Result → Safety findings → Limitations

This structure is important because a result that is valid for one clinical setting may become misleading when removed from its original context.

For example, a response rate in glabellar lines cannot be compared numerically with a response rate in pediatric spastic equinus. The studies use different populations and completely different definitions of treatment success.

Evidence Map at a Glance

Study 1 — Moderate-to-Severe Glabellar Lines

Population: Adults with moderate-to-severe glabellar frown lines
Randomized: 314 participants
Design: Prospective, randomized, double-blind, parallel, active-controlled, multicenter Phase III trial
Treatment: NBoNT versus onabotulinumtoxinA; 20 U studied in each group
Primary assessment: Investigator-assessed responder rate at maximum frown at week 4
Result: 93.7% versus 94.5%
Interpretation: Prespecified non-inferiority criterion met [1]

Study 2 — Essential Blepharospasm

Population: Patients with essential blepharospasm
ITT population: 60 patients
Design: Randomized, double-blind comparative trial
Treatment: Meditoxin versus Botox
Primary endpoint: Improvement in severity of spasm at 4 weeks
Result: 90.3% versus 86.2%
Interpretation: Non-inferiority criterion met in ITT and per-protocol analyses [2]

The publication explicitly describes Meditoxin as another name for Neuronox.

Study 3 — Cerebral-Palsy Spastic Equinus

Population: Children aged 2–10 years with cerebral palsy and spastic equinus gait
Eligible/randomized: 119 children; Neuronox 60, BOTOX 59
Design: Randomized, double-blinded, controlled multicentre clinical trial
Treatment: Calf-muscle injections; dose depended on hemiplegic or diplegic presentation
Primary endpoint: Response rate at week 12 based on the Physicians’ Rating Scale
Result: 48.3% versus 49.2%
Interpretation: Prespecified non-inferiority criterion met [3]

Study 4 — Post-Stroke Upper-Limb Spasticity

Population: Adults with moderate-to-severe upper-limb spasticity after stroke
Randomized: 196 patients; 98 per group
Design: Randomized, double-blind, multicenter, active-drug-controlled Phase III trial
Treatment: Neuronox versus BOTOX
Primary endpoint: Change from baseline in Modified Ashworth Scale at the wrist flexors at week 4
Result: −1.39 ± 0.79 versus −1.56 ± 0.81
Non-inferiority margin: 0.45
95% upper confidence limit: 0.40
Interpretation: Primary comparison remained within the prespecified non-inferiority margin [4]

What Does the Glabellar-Lines Trial Add to the Evidence Base?

The glabellar trial is particularly relevant to the aesthetic evidence base because it directly studied adults with moderate-to-severe glabellar frown lines. [1]

A total of 314 participants were randomized.

At week 4, the investigator-assessed responder rate at maximum frown was:

93.7% with NBoNT
versus
94.5% with onabotulinumtoxinA.

The trial's prespecified non-inferiority analysis was satisfied. [1]

This supports a specific conclusion: under the studied protocol and endpoint, NBoNT met the trial's statistical criterion for non-inferiority to the active comparator.

It does not establish superiority or universal interchangeability.

What Does the Blepharospasm Trial Add?

The essential-blepharospasm trial provides randomized comparative evidence in a therapeutic setting. [2]

The ITT population consisted of 60 patients, with 31 assigned to Meditoxin and 29 to Botox.

At four weeks, improvement in severity of spasm was reported in:

90.3% of the Meditoxin group
and
86.2% of the Botox group.

The study used a −15% non-inferiority threshold. The lower limits of the 95% confidence interval were −1.76% in the ITT analysis and −1.64% in the per-protocol analysis, remaining above the prespecified threshold. [2]

The study therefore supported non-inferiority for the primary comparison.

No significant between-group differences were reported for changes in eyelid closing force or functional visual status.

What Does the Cerebral-Palsy Trial Add?

The cerebral-palsy study extends the product-specific evidence base into a pediatric therapeutic population. [3]

The trial evaluated children aged 2–10 years with spastic equinus gait at three university hospitals.

Among 119 eligible participants, 60 received Neuronox and 59 received BOTOX.

Treatment was administered to the calf muscles at 4 U/kg in children with hemiplegia and 6 U/kg in children with diplegia under the study protocol. [3]

The primary outcome was response at week 12, defined as at least a 2-point increase in the Physicians’ Rating Scale.

The response rates were:

Neuronox: 48.3%
BOTOX: 49.2%

The trial used a −20% non-inferiority margin, and the 90% lower confidence limit for the difference was −11.58%, satisfying the prespecified criterion. [3]

Several secondary measures improved during follow-up in both groups, although individual secondary comparisons did not uniformly favor the same treatment.

This is why the primary non-inferiority result should not be expanded into a broad claim that the products produced identical outcomes in every measured domain.

What Does the Post-Stroke Trial Add?

The post-stroke trial is the largest therapeutic study in this four-trial evidence set. [4]

A total of 196 patients were randomized equally to Neuronox or BOTOX.

The trial was conducted at five university hospitals and assessed participants at baseline and weeks 4, 8 and 12.

The primary endpoint was change in the Modified Ashworth Scale at the wrist flexors at week 4.

The observed mean changes were:

Neuronox: −1.39 ± 0.79
BOTOX: −1.56 ± 0.81

The study defined a non-inferiority margin of 0.45, while the 95% upper confidence limit for the between-group difference was 0.40. [4]

The primary endpoint therefore satisfied the trial's non-inferiority criterion.

Both groups also showed significant improvements in several measures across follow-up, while most between-group secondary and safety comparisons were not statistically significant. One exception was reported for change in elbow-flexor MAS at week 12. [4]

Is There a Consistent Pattern Across the Four Trials?

There is one important pattern:

Each of these randomized comparative studies reported that its prespecified primary non-inferiority criterion was met. [1–4]

That is meaningful product-specific evidence.

However, the finding must be interpreted correctly.

It does not mean that all four studies collectively prove that Neuronox is identical to another product in every clinical situation.

Rather, each trial provides its own indication-specific conclusion under its own protocol.

The evidence is therefore strongest when described study by study.

What Do the Trials Say About Safety?

Safety was assessed in all four trials, but the methods, populations and follow-up periods differed. [1–4]

The glabellar study reported no serious adverse effects with either treatment. [1]

The blepharospasm trial reported adverse effects in 16.1% of the Meditoxin group and 27.6% of the Botox group, with no serious adverse events reported in either group. [2]

The cerebral-palsy trial reported no significant between-group difference in adverse-event frequency. [3]

The post-stroke study reported no significant differences in overall safety measures between groups under the study protocol. [4]

These findings are useful, but they should not be combined into a claim that Neuronox is universally safer than another product.

Safety evidence remains population-, dose-, indication- and follow-up-specific.

Why Should Secondary Outcomes Be Included?

A high-quality evidence summary should not report only the result most favorable to the product.

For example, the cerebral-palsy trial reported improvements in several secondary measures in both groups, while some individual GMFM comparisons favored BOTOX at particular visits. [3]

Similarly, the post-stroke study found no significant between-group differences in most secondary measures, but reported a statistically significant difference in one elbow-flexor MAS comparison at week 12. [4]

Keeping these findings visible prevents a non-inferiority trial from being transformed into an overly simplified promotional claim.

What About Funding and Conflicts of Interest?

Funding and conflict-of-interest disclosures are part of evidence appraisal and should remain visible.

The glabellar study disclosed industry sponsorship and an author-employment relationship. [1]

The blepharospasm publication disclosed funding from Pacific Pharmaceuticals and Medy-Tox. [2]

The post-stroke study disclosed industry sponsorship and reported that one investigator had received lecture honoraria from the sponsor. [4]

These disclosures do not automatically invalidate a study.

They are contextual information that readers should consider alongside randomization, blinding, endpoint selection, statistical analysis, completeness of reporting and replication.

What Does This Evidence Establish?

The four studies establish that Neuronox has been evaluated in multiple randomized, active-comparator clinical trials across both aesthetic and therapeutic populations. [1–4]

They provide product-specific data rather than relying solely on the general pharmacology of the BoNT-A class.

They also show that the primary comparisons in these studies satisfied their respective prespecified non-inferiority criteria.

What Does the Evidence Not Establish?

These trials do not establish that:

• Neuronox is superior to its comparators;

• Neuronox and another BoNT-A product are identical;

• all BoNT-A products are interchangeable;

• a 1:1 unit relationship can be generalized to every product or indication;

• therapeutic evidence automatically predicts aesthetic performance;

• results from one population apply to all patients;

• one combined efficacy percentage can meaningfully represent all four trials.

The phrase “non-inferior” should therefore remain non-inferior rather than being rewritten as “better,” “the same in every respect,” or “universally equivalent.”

Why Is This Evidence Base Clinically Interesting?

The important feature is not simply the number of publications.

It is that Neuronox has been investigated through randomized comparative designs in several distinct clinical settings, allowing readers to examine actual product-specific outcomes rather than infer performance solely from class mechanism. [1–4]

The evidence can therefore answer increasingly specific questions:

Was the actual product studied? — Yes.

Was it studied in randomized comparative trials? — Yes, in this evidence set.

Was it studied in more than one clinical setting? — Yes.

Did the primary analyses in these four studies meet their prespecified non-inferiority criteria? — Yes.

The next question is not “Is Neuronox universally better?”

The more scientifically useful question is:

What exactly did each trial demonstrate in its own population and clinical setting?

That is the focus of BW-05 through BW-08.

References

1. Won CH, Lee HM, Lee WS, Kang H, Kim BJ, Kim WS, Lee JH, Lee DH, Huh CH. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study. Dermatol Surg. 2013;39(1 Pt 2):171–178. doi:10.1111/dsu.12072. PMID:23301821.

2. Yoon JS, Kim JC, Lee SY. Double-blind, randomized, comparative study of Meditoxin versus Botox in the treatment of essential blepharospasm. Korean J Ophthalmol. 2009;23(3):137–141. doi:10.3341/kjo.2009.23.3.137. PMID:19794937.

3. Kim K, Shin HI, Kwon BS, Kim SJ, Jung IY, Bang MS. Neuronox versus BOTOX for spastic equinus gait in children with cerebral palsy: a randomized, double-blinded, controlled multicentre clinical trial. Dev Med Child Neurol. 2011;53(3):239–244. doi:10.1111/j.1469-8749.2010.03830.x. PMID:21087238.

4. Seo HG, Paik NJ, Lee SU, Oh BM, Chun MH, Kwon BS, Bang MS. Neuronox versus BOTOX in the treatment of post-stroke upper limb spasticity: a multicenter randomized controlled trial. PLoS One. 2015;10(6):e0128633. doi:10.1371/journal.pone.0128633. PMID:26030192. ClinicalTrials.gov: NCT01313767.

• COMPLETE SITE INDEX

BotoxWiki provides evidence-focused educational content with transparent sourcing and editorial standards.

Clinical & Anatomy

Evidence & Review

Editorial & Trust

Reference Standard

BotoxWiki provides evidence-based content, medical review, and a neutral editorial approach to botulinum toxin formulations and anatomical guidance.

© BotoxWiki Clinical Reference Directory.